Avac Event

PrEPVacc: An in-depth look at the trial, and what’s next

During this webinar, the PrEPVacc team and AVAC reviewed the status of the PrEPVacc trial. PrEPVacc, a 3-in-1 trial testing two different vaccine candidates (plus placebo arm) and two daily oral PrEP regimens, recently discontinued vaccinations in the trial due to an independent data review board’s conclusion that the vaccines were having no effect in preventing HIV infection. On this call, we will review key aspects of PrEPVacc, including its innovative study design, implementation, integrated social science, and data analysis plans. Speakers engaged in conversation about what we’ve learned from PrEPVacc, what we can still learn, and what this may mean for the HIV prevention field.

  • PrEPVacc Trial Design: Sheena McCormack, PrEPVacc Project Lead, MRC Clinical Trials Unit, University College London, UK
  • Trial Implementation and Baseline Data: Eugene Ruzagira, PrEPVacc Trial Director, MRC/UVRI & LSHTM Uganda Research Unit
  • Integrated Social Science: Rachel Kawuma, PrEPVacc Social Scientist, MRC/UVRI & LSHTM Uganda Research Unit
  • Analysis Plan: Sheila Kansiime, PrEPVacc Statistician, MRC/UVRI & LSHTM Uganda Research Unit

Recording / Sheena McCormack Slides / Eugene Ruzagira Slides / Rachel Kawuma Slides / Sheila Kansiime Slides